Biblio Discovery — Demo Discovery Service

6 hasil untuk "Mathiot, Laurent"

Menampilkan 1–6 · 0,05 detik · RSS

  1. Artikel Jurnal Teks lengkap

    HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature

    Mathiot, Laurent; Herbreteau, Guillaume; Robin, Siméon dkk.

    Curr Oncol · 2022 · Inggris · PubMed Central

    Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding…

  2. Artikel Jurnal Teks lengkap

    Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature

    Aubert, Marine; Mathiot, Laurent; Vegas, Hélène dkk.

    Oncologist · 2024 · Inggris · PubMed Central

    BACKGROUND: In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When platinum resistant, subsequent lines of chemotherapy are of limited effect and often poorly tolerated…

  3. Artikel Jurnal Teks lengkap

    Monitoring concentration and lipid signature of plasma extracellular vesicles from HR(+) metastatic breast cancer patients under CDK4/6 inhibitors treatment

    Richard, Mathilde; Moreau, Rosalie; Croyal, Mikaël dkk.

    J Extracell Biol · 2024 · Inggris · PubMed Central

    Extracellular vesicles (EVs) are cell‐derived small membrane structures that transport various molecules. They have emerged as potential circulating biomarkers for monitoring responses to cancer therapies. This study aimed to comprehensively characterize plasma‐carried EVs in hormone…

  4. Artikel Jurnal Teks lengkap

    Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

    Mathiot, Laurent; Combarel, David; Cagnat, Justin dkk.

    J Immunother Cancer · 2024 · Inggris · PubMed Central

    Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion protein, combines interleukin-2 (IL-2) with an…

  5. Artikel Jurnal Teks lengkap

    Real-world analysis of HER2-ultralow in HR+/HER2– metastatic breast cancer: prevalence and first-line chemotherapy outcomes

    Mathiot, Laurent; Kerdraon, Olivier; Le Borgne, Florent dkk.

    Ther Adv Med Oncol · 2025 · Inggris · PubMed Central

    BACKGROUND: HER2-ultralow is an emerging subgroup of metastatic breast cancer (mBC). However, despite an increasing interest, limited data exist on its prevalence and outcomes, especially among patients receiving standard first-line chemotherapy. OBJECTIVES: This study assessed the prevalence and…

  6. Artikel Jurnal Teks lengkap

    Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study

    Frenel, Jean-Sébastien; Mathiot, Laurent; Cropet, Claire dkk.

    J Immunother Cancer · 2025 · Inggris · PubMed Central

    BACKGROUND: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort. METHODS: Patients…